GLPG

Galapagos NV [GLPG] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

GLPG Stock Summary

Top 10 Correlated ETFs

GLPG


Top 10 Correlated Stocks

GLPG


In the News

10:36 29 Mar 2024 GLPG

Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround

Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

09:46 29 Mar 2024 GLPG

Buy These 4 Low-Beta Stocks to Counter Market Volatility

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Virco Mfg (VIRC), Galapagos NV (GLPG), Axonics (AXNX) and Stride (LRN) are well-poised to gain.

07:32 29 Mar 2024 GLPG

New Strong Buy Stocks for December 13th

TZOO, GLPG, BBVA, TW and STNE have been added to the Zacks Rank #1 (Strong Buy) List on December 13, 2023.

09:14 29 Mar 2024 GLPG

Galapagos NV (GLPG) Q3 2023 Earnings Call Transcript

Galapagos NV (NASDAQ:GLPG ) Q3 2023 Earnings Conference Call November 3, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO & COO Jeevan Shetty - Head of Clinical Development, Oncology Conference Call Participants Xian Deng - UBS Dane Leone - Raymond James Johoon Kim - RBC Capital Markets Jason Gerberry - Bank of America Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day, and thank you for standing by. Welcome to the Galapagos Q3 2023 Financial Results Conference Call.

04:30 29 Mar 2024 GLPG

Galapagos NV (GLPG) Q2 2023 Earnings Call Transcript

Galapagos NV (NASDAQ:GLPG ) Q2 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO and COO Michele Manto - Chief Commercial Officer Daniele D'Ambrosio - Head of Immunology Conference Call Participants Emily Field - Barclays Jason Gerberry - Bank of America Mike Ulz - Morgan Stanley Brian Balchin - Jefferies Xian Deng - UBS Phil Nadeau - TD Cowen Dane Leone - Raymond James Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day and thank you for standing by. Welcome to the Galapagos H1 2023 Financial Results Conference Call.

01:59 29 Mar 2024 GLPG

Galapagos Stands Strong On Jyseleca Positive Clinical Data

Galapagos' focuses on immunology and oncology, with its flagship Jyseleca being used to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. The company is also developing CAR-T therapies with encouraging initial safety and efficacy data presented from ongoing Phase 1/2 studies.

10:35 29 Mar 2024 GLPG

Galapagos NV (GLPG) Q4 2022 Earnings Call Transcript

Galapagos NV (NASDAQ:GLPG ) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & President Daniele D'Ambrosio - Head of Immunology Michele Manto - Chief Commercial Officer Conference Call Participants Phil Nadeau - Cowen Peter Verdult - Citi Brian Abrahams - RBC Capital Markets Rosie Turner - Jefferies Dane Leone - Raymond James Suzanne van Voorthuizen - Kempen Operator Good day and thank you for standing by. Welcome to the Galapagos Full Year 2022 Financial Results Call and Webcast.

07:07 29 Mar 2024 GLPG

Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating

On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the stock is still hovering around negative $2.0Bn enterprise value territory.

08:35 29 Mar 2024 GLPG

Galapagos shares down after announcing clinical-trial miss for Crohn's disease

U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn's disease missed the primary endpoints in a Phase 3 clinical trial. The drug, filgotinib, is approved to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan.

04:01 29 Mar 2024 GLPG

Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference

Mechelen, Belgium; 3 January 202 3 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 4 1t h Annual J.P. Morgan Healthcare Conference on January 9 -1 2 , 202 3 .

GLPG Financial details

Company Rating
Buy
Market Cap
2.16B
Income
-153.07M
Revenue
543.97M
Book val./share
39.78
Cash/share
57.84
Dividend
-
Dividend %
-
Employees
1.34K
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-16.56
Forward P/E
-24.37
PEG
5.74
P/S
4.63
P/B
0.97
P/C
0.56
P/FCF
-4.68
Quick Ratio
8.75
Current Ratio
8.91
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
-2.36
EPS next Y
-1.32
EPS next Q
-0.2
EPS this Y
-196.69%
EPS next Y
-44.2%
EPS next 5Y
-45.05%
EPS last 5Y
5.21%
Revenue last 5Y
-22.27%
Revenue Q/Q
-19.96%
EPS Q/Q
400.64%
-
-
-
-
SMA20
-10.81%
SMA50
-17.5%
SMA100
-2.94%
Inst Own
25.5%
Inst Trans
0.87%
ROA
-3%
ROE
-6%
ROC
-0.04%
Gross Margin
97%
Oper. Margin
-28%
Profit Margin
-28%
Payout
-
Shs Outstand
65.9M
Shs Float
65.27M
-
-
-
-
Target Price
88.89
52W Range
31.86-45.21
52W High
-28.51%
52W Low
+3.77%
RSI
27
Rel Volume
2.23
Avg Volume
121.44K
Volume
270.51K
Perf Week
-5.27%
Perf Month
-18.66%
Perf Quarter
-9.58%
Perf Half Y
-7.32%
-
-
-
-
Beta
0.027
-
-
Volatility
0.35%, 2.06%
Prev Close
-2.37%
Price
32.17
Change
-1.44%

GLPG Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
14.677.357.47.73.63
Net income per share
2.6-4.78-1.91-3.323.21
Operating cash flow per share
55.69-6.57-7.69-7.620
Free cash flow per share
54.9-7.97-8.58-8.190
Cash per share
100.3479.3371.862.350
Book value per share
49.9141.0440.3638.470
Tangible book value per share
49.484039.4435.180
Share holders equity per share
49.9141.0440.3638.470
Interest debt per share
0.460.60.590.440
Market cap
10.59B5.27B3.19B2.73B2.43B
Enterprise value
8.75B3.16B982.02M2.25B0
P/E ratio
70.66-16.94-25.42-12.5311.46
Price to sales ratio
12.5311.026.585.4110.12
POCF ratio
3.3-12.33-6.33-5.460
PFCF ratio
3.35-10.16-5.68-5.080
P/B Ratio
3.681.971.211.080
PTB ratio
3.681.971.211.080
EV to sales
10.366.612.034.440
Enterprise value over EBITDA
22.43-19.11-7.12-11.570
EV to operating cash flow
2.73-7.4-1.95-4.490
EV to free cash flow
2.77-6.1-1.75-4.180
Earnings yield
0.01-0.06-0.04-0.080.09
Free cash flow yield
0.3-0.1-0.18-0.20
Debt to equity
0.010.010.010.010
Debt to assets
00.010.0100
Net debt to EBITDA
-4.7112.7315.992.510
Current ratio
10.268.458.588.110
Interest coverage
284.4-19.03-14.21-38.40
Income quality
21.411.44.882.30
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.080.20.20.370
Research and developement to revenue
0.511.11.011.021.01
Intangibles to total assets
00.010.010.050
Capex to operating cash flow
-0.010.210.110.070
Capex to revenue
-0.05-0.19-0.12-0.070
Capex to depreciation
-3.67-4.89-1.67-0.560
Stock based compensation to revenue
0.050.170.150.180
Graham number
54.0466.4441.753.610
ROIC
0.13-0.07-0.06-0.110
Return on tangible assets
0.02-0.06-0.02-0.050
Graham Net
45.9634.4934.5130.010
Working capital
5.29B4.73B4.3B3.71B0
Tangible asset value
2.85B2.6B2.58B2.31B0
Net current asset value
2.67B2.32B2.31B2.03B0
Invested capital
0.010.010.010.010
Average receivables
56.82M126.75M151M102.97M0
Average payables
105.27M156.91M152.81M133.8M0
Average inventory
265.5K305K10.46M36.75M0
Days sales outstanding
34.6132.3996.8155.870
Days payables outstanding
121.73119.4130.09K4.03K0
Days of inventory on hand
0.220.254.61K1.6K0
Receivables turnover
10.552.763.776.530
Payables turnover
33.060.010.090
Inventory turnover
1.68K1.48K0.080.230
ROE
0.05-0.12-0.05-0.090
Capex per share
-0.79-1.4-0.88-0.560

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.071.462.712.291.82
Net income per share
0.33-3.180.350.080.39
Operating cash flow per share
-1.78-2.76-1.44-1.92-1.8
Free cash flow per share
-1.95-2.88-1.5-1.98-1.85
Cash per share
66.2662.7560.5559.2957.84
Book value per share
40.8738.7138.9239.5339.78
Tangible book value per share
37.6235.435.7236.3836.71
Share holders equity per share
40.8738.7138.9239.5339.78
Interest debt per share
0.410.250.280.210.28
Market cap
2.86B2.71B2.55B2.45B2.17B
Enterprise value
2.2B2.23B2.44B2.36B2.03B
P/E ratio
33.12-3.2727.43119.8421.02
Price to sales ratio
20.9728.5314.2416.3118.1
POCF ratio
-24.42-15.09-26.84-19.5-18.28
PFCF ratio
-22.19-14.46-25.68-18.92-17.8
P/B Ratio
1.061.070.990.950.83
PTB ratio
1.061.070.990.950.83
EV to sales
16.1723.4213.6315.7616.89
Enterprise value over EBITDA
-83.33-19.9169.01333.71-324.79
EV to operating cash flow
-18.84-12.39-25.7-18.84-17.06
EV to free cash flow
-17.12-11.87-24.59-18.28-16.61
Earnings yield
0.01-0.080.0100.01
Free cash flow yield
-0.05-0.07-0.04-0.05-0.06
Debt to equity
0.010.010.010.010.01
Debt to assets
00000
Net debt to EBITDA
24.694.35-3.06-11.6723.27
Current ratio
8.388.117.958.498.91
Interest coverage
-8.5324.3310.137.15-7.39
Income quality
-5.430.87-4.09-24.59-4.6
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.320.620.160.320.14
Research and developement to revenue
0.841.590.580.720.84
Intangibles to total assets
0.040.050.050.050.05
Capex to operating cash flow
0.10.040.050.030.03
Capex to revenue
-0.09-0.08-0.02-0.03-0.03
Capex to depreciation
-2-0.360-0.210.17
Stock based compensation to revenue
0.140.3900.18-0.23
Graham number
17.3552.5917.568.3318.73
ROIC
-0.01-0.050.010-0.01
Return on tangible assets
0-0.050.0100.01
Graham Net
32.4130.230.3430.7831.33
Working capital
3.93B3.71B3.63B3.56B3.51B
Tangible asset value
2.48B2.31B2.35B2.38B2.42B
Net current asset value
2.18B2.03B2.09B2.09B2.13B
Invested capital
0.010.010.010.010.01
Average receivables
59.22M65.86M72.46M67.57M70.31M
Average payables
157.75M144.02M144.62M143.51M126.1M
Average inventory
26.26M39.22M52.35M50.32M52.24M
Days sales outstanding
35.9373.183440.5654.77
Days payables outstanding
5.82K2.9K3.93K2.76K1.91K
Days of inventory on hand
959.421.15K1.3K1.03K877.97
Receivables turnover
2.51.232.652.221.64
Payables turnover
0.020.030.020.030.05
Inventory turnover
0.090.080.070.090.1
ROE
0.01-0.080.0100.01
Capex per share
-0.18-0.12-0.07-0.06-0.05

GLPG Frequently Asked Questions

What is Galapagos NV stock symbol ?

Galapagos NV is a BE stock and trading under the symbol GLPG

Is Galapagos NV buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $88.89. The lowest prediction is $83.74389562 and the highest is $97

What is GLPG stock prediction ?

What is Galapagos NV stock quote today ?

Galapagos NV stock price is $32.17 today.

Is Galapagos NV stock public?

Yes, Galapagos NV is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap